Indivior Pharmaceuticals (INDV) Current Assets (2021 - 2026)

Indivior Pharmaceuticals' Current Assets history runs 6 years deep, the most recent figure standing at $667.0 million for Q1 2026.

• On a quarterly basis, Current Assets fell 24.46% year-over-year to $667.0 million in Q1 2026; TTM through Mar 2026 was $667.0 million, a 24.46% decrease from a year earlier, with the FY2025 full-year figure at $652.0 million, down 21.16% from the prior year.
• Current Assets climbed to $667.0 million in Q1 2026 per INDV's latest filing, from $652.0 million in the prior quarter.
• Across five years, Current Assets topped out at $1.3 billion in Q4 2022 and bottomed at $652.0 million in Q4 2025.
• The 5-year median for Current Assets is $902.5 million (2025), against an average of $927.2 million.
• Across the five-year window, Current Assets decreased 0.16% in 2023 and sank 34.21% in 2024, its largest moves.
• Year by year, Current Assets stood at $1.3 billion in 2022, then fell by 0.16% to $1.3 billion in 2023, then sank by 34.21% to $827.0 million in 2024, then declined by 21.16% to $652.0 million in 2025, then rose by 2.3% to $667.0 million in 2026.
• Per Business Quant, the three latest INDV Current Assets figures stand at $667.0 million (Q1 2026), $652.0 million (Q4 2025), and $922.0 million (Q3 2025).